Skip to main content
. 2019 Sep 5;29(9):347–353. doi: 10.2188/jea.JE20180112

Table 2. 1-, 3-, 5-, and 10-year relative survival of patients with SCLC stratified by disease stage.

Relative survival (%) Years since diagnosis
1 3 5 10




Survival (95% CI) Survival (95% CI) Survival (95% CI) Survival (95% CI)
Limited Disease (LD)                
Period 1 (1993–1998) 56.8 (54.3–59.1) 20.3 (18.3–22.3) 16.8 (14.9–18.7) 12.4 (10.6–14.4)
Period 2 (1999–2001) 63.6 (60.5–66.6) 26.2 (23.4–29.1) 21.1 (18.4–23.8) 16.1 (13.5–18.8)
Period 3 (2002–2006) 66.9 (64.5–69.2) 27.0 (24.8–29.3) 19.9 (17.8–22.0)    
Period 3 (perioda) 66.2 (63.8–68.5) 27.2 (25.0–29.5) 21.4 (19.3–23.6) 15.6 (13.4–18.0)
Extensive Disease (ED)                
Period 1 (1993–1998) 27.7 (25.6–29.8) 3.4 (2.6–4.4) 2.3 (1.6–3.1) 1.2 (0.7–1.8)
Period 2 (1999–2001) 33.0 (30.1–35.9) 5.2 (3.9–6.7) 2.8 (1.9–4.0) 1.7 (1.0–2.9)
Period 3 (2002–2006) 34.3 (32.3–36.4) 4.3 (3.5–5.3) 2.0 (1.4–2.7)    
Period 3 (perioda) 34.8 (32.8–36.9) 5.0 (4.0–6.0) 2.7 (2.0–3.6) 1.4 (0.8–2.3)

CI, confidence interval; ED, extensive disease; LD, limited disease; SCLC, small-cell lung cancer.

aRelative survival and CIs were estimated using the period method. Survival data of patients followed between 2002 and 2006 were used.